Acromegaly - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acromegaly - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acromegaly - Pipeline Review, H1 2015', provides an overview of the Acromegaly's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acromegaly
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acromegaly and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acromegaly products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acromegaly pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acromegaly
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acromegaly Overview 9
Therapeutics Development 10
Pipeline Products for Acromegaly - Overview 10
Pipeline Products for Acromegaly - Comparative Analysis 11
Acromegaly - Therapeutics under Development by Companies 12
Acromegaly - Therapeutics under Investigation by Universities/Institutes 13
Acromegaly - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Acromegaly - Products under Development by Companies 17
Acromegaly - Products under Investigation by Universities/Institutes 19
Acromegaly - Companies Involved in Therapeutics Development 20
Aegis Therapeutics, LLC 20
Antisense Therapeutics Limited 21
Chiasma, Inc. 22
Crinetics Pharmaceuticals, Inc. 23
DexTech Medical AB 24
Foresee Pharmaceuticals, LLC 25
GP Pharm, S.A. 26
Ipsen S.A. 27
Isis Pharmaceuticals, Inc. 28
Italfarmaco S.p.A. 29
Novartis AG 30
Paladin Labs Inc. 31
Peptron, Inc. 32
Sompharmaceuticals S.A. 33
Acromegaly - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
ATL-1103 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
BIM-23A758 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DG-3173 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
FP-002 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
G-02113 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ISIS-GHRLRx - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ITF-2984 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
L-779976 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
octreotide - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
octreotide acetate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
octreotide acetate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
octreotide acetate LAR - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
octreotide acetate long acting - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
octreotide acetate SR - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
octreotide SR - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
pasireotide LAR - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
pegvisomant - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Somadex - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
SXN-101742 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
SXN-101959 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Acromegaly - Recent Pipeline Updates 69
Acromegaly - Dormant Projects 79
Acromegaly - Discontinued Products 80
Acromegaly - Product Development Milestones 81
Featured News & Press Releases 81
Apr 16, 2015: ATL1103 - New European Patent Application Allowance 81
Mar 06, 2015: ATL1103 Phase II Trial Data to be presented at ENDO 2015 81
Mar 05, 2015: ATL1103 Higher Dose Study to Support Phase III to Commence 82
Mar 05, 2015: Chiasma Announces New Data for Investigational Octreotide Capsules 82
Feb 09, 2015: Newly Published Phase III Study Results Show Positive Outcomes for Octreotide Capsules in People with Acromegaly 84
Jan 26, 2015: Glide Appoints Albany Molecular Research for Manufacture of Novel Octreotide Solid Dose Formulation Clinical Trial Product 85
Dec 16, 2014: Novartis gains FDA approval for Signifor LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder 86
Dec 09, 2014: Antisense Therapeutics Provides ATL-1103 Update 87
Oct 17, 2014: Antisense Therapeutics Provides Update On ATL1103 For Acromegaly 88
Sep 26, 2014: Novartis drug Signifor LAR recommended by CHMP for EU approval to treat patients with rare hormonal disorder acromegaly 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List of Tables

Number of Products under Development for Acromegaly, H1 2015 10
Number of Products under Development for Acromegaly - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2015 19
Acromegaly - Pipeline by Aegis Therapeutics, LLC, H1 2015 20
Acromegaly - Pipeline by Antisense Therapeutics Limited, H1 2015 21
Acromegaly - Pipeline by Chiasma, Inc., H1 2015 22
Acromegaly - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015 23
Acromegaly - Pipeline by DexTech Medical AB, H1 2015 24
Acromegaly - Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 25
Acromegaly - Pipeline by GP Pharm, S.A., H1 2015 26
Acromegaly - Pipeline by Ipsen S.A., H1 2015 27
Acromegaly - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 28
Acromegaly - Pipeline by Italfarmaco S.p.A., H1 2015 29
Acromegaly - Pipeline by Novartis AG, H1 2015 30
Acromegaly - Pipeline by Paladin Labs Inc., H1 2015 31
Acromegaly - Pipeline by Peptron, Inc., H1 2015 32
Acromegaly - Pipeline by Sompharmaceuticals S.A., H1 2015 33
Assessment by Monotherapy Products, H1 2015 34
Number of Products by Stage and Target, H1 2015 36
Number of Products by Stage and Mechanism of Action, H1 2015 38
Number of Products by Stage and Route of Administration, H1 2015 40
Number of Products by Stage and Molecule Type, H1 2015 42
Acromegaly Therapeutics - Recent Pipeline Updates, H1 2015 69
Acromegaly - Dormant Projects, H1 2015 79
Acromegaly - Discontinued Products, H1 2015 80